LYEL / Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

Lyell is a developer of personalized T-cell therapies for solid tumors, with two programs targeting various types of solid tumors. Their pipeline incl more_horizontal

It was another wild ride in the stock market today. Whether you were trading penny stocks or Tesla, the thing weighing on everyone's conscience was th more_horizontal

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming compan more_horizontal

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the more_horizontal

Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreeme more_horizontal

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so more_horizontal

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so more_horizontal

The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in so more_horizontal